Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The unmet need in DLBCL

Georg Lenz • 18 Apr 2016
EHA 2016
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Rituximab

Georg Lenz from the University of Münster, Münster, Germany discusses the current unmet need in diffuse large B-cell lymphoma (DLBCL), which he states to be patients who do not respond to the current standard treatment of rituximab plus CHOP chemotherapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Georg Lenz

1:29
Update from the Lenz lab in Münster
Georg Lenz • 20 Jun 2019
0:55
DLBCL research to watch
Georg Lenz • 20 Jun 2019
1:26
Can we improve on R-CHOP for the frontline treatment of DLBCL?
Georg Lenz • 20 Jun 2019
1:08
The importance of recgonizing different DLBCL subtypes
Georg Lenz • 9 Jun 2016

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals